Stock comparison
ELI LILLY & Co is 589.5x more valuable than UroGen Pharma Ltd. by market capitalization ($1.142 T vs $1.94 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
LLY is larger
ELI LILLY & Co is 589.5x more valuable than UroGen Pharma Ltd. by market capitalization ($1.142 T vs $1.94 B).
Market value leader
LLY
ELI LILLY & Co is 589.5x more valuable than UroGen Pharma Ltd. by market capitalization ($1.142 T vs $1.94 B).
Revenue leader
LLY
URGN: $109.79M vs LLY: $65.18B.
Profit leader
LLY
URGN: -$153.49M vs LLY: $20.64B.
Margin leader
LLY
URGN: -139.8% vs LLY: 31.7% net margin.
| Metric | URGN | LLY |
|---|---|---|
| Market cap | $1.94 B | $1.142 T |
| US-listed rank | #2165 | #10 |
| Revenue (latest FY) | $109.79M | $65.18B |
| Net income (latest FY) | -$153.49M | $20.64B |
| Net margin | -139.8% | 31.7% |
| P/E (trailing FY) | - | 55.3x |
| SEC filings | 548 | 995 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ELI LILLY & Co is 589.5x more valuable than UroGen Pharma Ltd. by market capitalization ($1.142 T vs $1.94 B).
In their latest fiscal years, UroGen Pharma Ltd. reported $109.79M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: UroGen Pharma Ltd. and ELI LILLY & Co, or browse the full rankings.